Armata Pharmaceuticals, Inc.
ARMP
$2.47
$0.041.65%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 84.67% | 0.00% | 14.24% | 34.92% | -10.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 84.67% | 0.00% | 14.24% | 34.92% | -10.71% |
| Cost of Revenue | -4.01% | -19.17% | -16.60% | 50.44% | 15.27% |
| Gross Profit | 12.79% | 21.19% | 19.62% | -53.11% | -18.69% |
| SG&A Expenses | -7.03% | 7.88% | 13.17% | 26.84% | 61.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.82% | 1.41% | 4.83% | 2.74% | 3.82% |
| Operating Income | 15.99% | -1.58% | -3.78% | 0.39% | -5.34% |
| Income Before Tax | 61.66% | 99.46% | 72.60% | 30.50% | -81.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.66% | 99.46% | 72.60% | 30.50% | -81.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.66% | 99.46% | 72.60% | 30.50% | -81.37% |
| EBIT | 15.99% | -1.58% | -3.78% | 0.39% | -5.34% |
| EBITDA | 17.15% | -0.78% | -2.99% | 1.17% | -4.91% |
| EPS Basic | 61.76% | 99.47% | 72.63% | 30.58% | -81.14% |
| Normalized Basic EPS | 1.16% | -18.40% | -20.79% | -16.27% | -22.34% |
| EPS Diluted | 43.78% | 50.76% | 18.60% | 4.82% | -113.94% |
| Normalized Diluted EPS | 11.51% | 9.29% | -4.36% | -12.67% | -19.03% |
| Average Basic Shares Outstanding | 0.19% | 0.22% | 0.24% | 0.22% | 0.19% |
| Average Diluted Shares Outstanding | 14.63% | 29.19% | 15.08% | 1.17% | 1.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |